Deutsche Bank Comments On Gilead Sciences Client Dinner

According to Deutsche Bank, it met with Gilead Sciences GILD management. Deutsche Bank said that it hosted a client dinner with COO John Milligan last night. “Co sees B-tripla as potentially being the "kindler gentler Atripla," with potential for uptake where Sustiva is not preferred. According to the Gilead, there may be 3-4% of centers (clustered) where Sustiva isn't preferred, as well as other populations (African American, women of child-bearing age) where Sustiva is not used. These might be earlier adopters of B-tripla use, converting current Truvada based patients to B-tripla (better economics for Gilead) . The co believes QUAD will be viewed as more robust and take share from Atripla. Net/net combined - both could grow Gilead HIV sales from uptake in different market segments.” Gilead Sciences closed yesterday at $40.68.